Sun, Jan 25, 2015, 10:31 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • thegreen_o thegreen_o Dec 6, 2012 10:46 AM Flag

    Motley " 1 BIOTECH Wall Street Thinks Has MULTIBAGGER Potiental" (SRPT) link


    1 Biotech Wall Street Thinks Has Multibagger Potential
    By David Williamson and Brenton Flynn | More Articles | Save For Later
    November 22, 2012 | Comments (0)
    Sarepta (Nasdaq: SRPT ) Piper Jaffray has the company going up to somewhere between $60 and $80 in the near term and, staggeringly, suggests the potential for the stock to hit as high as $160 per share. In this video, Motley Fool health-care analyst David Williamson talks about how this relates to the company's tremendous results with its Duchenne muscular dystrophy drug eteplirsen, and how specific catalysts in the weeks and months to come could propel shares higher.

    Sentiment: Strong Buy

    This topic is deleted.
12.18-0.05(-0.37%)Jan 23 3:59 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.